RHYTHM PHARMACEUTICALS, INC. (RYTM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 123.59M USD | Liabilities, Current |
| Cash and equivalents | 65.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 40.41M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 30.52M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $123.59M | $65.61M | (m) | $40.41M | $30.52M | (m) |
| 2026-03-31 | (m) | $103.20M | $62.14M | (m) | $34.19M | $28.65M | (m) |
| 2025-12-31 | (m) | $105.94M | $54.30M | (m) | $26.08M | $25.75M | (m) |
| 2025-09-30 | (m) | $104.27M | $52.08M | (m) | $33.03M | $22.11M | (m) |
| 2025-06-30 | (m) | $129.46M | $135.59M | (m) | $26.12M | $18.87M | (m) |
| 2025-03-31 | (m) | $111.82M | $106.09M | (m) | $17.82M | $19.32M | (m) |
| 2024-12-31 | (m) | $115.52M | $89.14M | (m) | $18.51M | $18.74M | (m) |
| 2024-09-30 | (m) | $97.61M | $47.52M | (m) | $19.31M | $13.89M | (m) |
| 2024-06-30 | (m) | $54.72M | $161.67M | (m) | $17.60M | $11.99M | (m) |
| 2024-03-31 | (m) | $54.16M | $53.43M | (m) | $14.70M | $8.51M | (m) |
| 2023-12-31 | (m) | $55.20M | $60.08M | (m) | $14.87M | $8.62M | (m) |
| 2023-09-30 | (m) | $50.14M | $64.59M | (m) | $14.54M | $7.76M | (m) |
| 2023-06-30 | (m) | $46.10M | $115.68M | (m) | $13.83M | $6.18M | (m) |
| 2023-03-31 | (m) | $46.03M | $109.66M | (m) | $8.12M | $5.49M | (m) |
| 2022-12-31 | (m) | $39.81M | $127.68M | (m) | $6.22M | $2.92M | (m) |
| 2022-09-30 | (m) | $33.10M | $185.09M | (m) | $3.33M | (m) | (m) |
| 2022-06-30 | (m) | $44.57M | $113.21M | (m) | $1.71M | (m) | (m) |
| 2022-03-31 | (m) | $47.27M | $78.54M | (m) | $862.00K | (m) | (m) |
| 2021-12-31 | (m) | $43.43M | $59.25M | (m) | $1.02M | $111.00K | (m) |
| 2021-09-30 | (m) | $23.47M | $92.37M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $17.46M | $69.34M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $16.85M | $87.27M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $17.99M | $100.85M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $15.85M | $67.67M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $14.90M | $59.09M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $17.70M | $55.78M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $24.42M | $62.29M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $25.21M | $71.68M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $26.09M | $63.12M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $12.57M | $42.02M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $13.58M | $49.54M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $7.80M | $58.25M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.25M | $210.48M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.58M | $43.17M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $6.72M | $34.24M | $113.85M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $5.46M | $27.91M | $2.50M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $4.73M | $6.54M | $4.00M | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $12.62M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $34.87M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $152.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |